ClinicaliQ Trial Snapshot
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Active Not Recruiting • Phase III • Oncology • NCT06608927.
- Adding quemliclustat to standard chemotherapy did not improve survival in advanced pancreatic cancer compared to chemotherapy alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients. Conditions: Metastatic Pancreatic Ductal Adenocarcinoma Interventions: Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine Lead Sponsor: Arcus Biosciences, Inc. Planned Enrollment: 610 participants